Methodology and Applications of Disease Biomarker Identification in Human Serum

Biomarkers are biomolecules that serve as indicators of biological and pathological processes, or physiological and pharmacological responses to a drug treatment. Because of the high abundance of albumin and heterogeneity of plasma lipoproteins and glycoproteins, biomarkers are difficult to identify in human serum. Due to the clinical significance the identification of disease biomarkers in serum holds great promise for personalized medicine, especially for disease diagnosis and prognosis. This review summarizes some common and emerging proteomics techniques utilized in the separation of serum samples and identification of disease signatures. The practical application of each protein separation or identification technique is analyzed using specific examples. Biomarkers of cancers of prostate, breast, ovary, and lung in human serum have been reviewed, as well as those of heart disease, arthritis, asthma, and cystic fibrosis. Despite the advancement of technology few biomarkers have been approved by the Food and Drug Administration for disease diagnosis and prognosis due to the complexity of structure and function of protein biomarkers and lack of high sensitivity, specificity, and reproducibility for those putative biomarkers. The combination of different types of technologies and statistical analysis may provide more effective methods to identify and validate new disease biomarkers in blood.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  F. Regnier,et al.  High-performance liquid chromatography of biopolymers. , 1983, Science.

[3]  G. Sensabaugh,et al.  Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. , 1978, Journal of forensic sciences.

[4]  P. O’Farrell High resolution two-dimensional electrophoresis of proteins. , 1975, The Journal of biological chemistry.

[5]  Edward R. Ashwood,et al.  Tietz Fundamentals of Clinical Chemistry , 1996 .

[6]  S. Somiari,et al.  Functional relationship and gene ontology classification of breast cancer biomarkers. , 2003, The International journal of biological markers.

[7]  A. Brandes,et al.  Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. , 2003, Anticancer research.

[8]  A. Branchi,et al.  Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects , 2000, International journal of clinical & laboratory research.

[9]  A. Balduini,et al.  Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.

[10]  W. Stolz,et al.  Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.

[11]  W. Winnik Continuous pH/salt gradient and peptide score for strong cation exchange chromatography in 2D-nano-LC/MS/MS peptide identification for proteomics. , 2005, Analytical chemistry.

[12]  F. Miller,et al.  Use of two-dimensional liquid fractionation for separation of proteins from cell lysates without the presence of methionine oxidation. , 2004, Journal of chromatography. A.

[13]  O. Dirsch,et al.  Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. , 2004, Thyroid : official journal of the American Thyroid Association.

[14]  S. Barnhill,et al.  CA 125: The past and the Future , 1998, The International journal of biological markers.

[15]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[16]  P. McCullough,et al.  Sorting out the evidence on natriuretic peptides. , 2003, Reviews in cardiovascular medicine.

[17]  R. Bischoff,et al.  Methodological advances in the discovery of protein and peptide disease markers. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  A. Taniguchi,et al.  Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[19]  A simple and inexpensive approach to interfacing high‐performance liquid chromatography and matrix‐assisted laser desorption/ionization‐time of flight‐mass spectrometry , 2004, Proteomics.

[20]  Shi-Nae Park,et al.  Serum Heat Shock Protein 70 and its Correlation with Clinical Characteristics in Patients with Sudden Sensorineural Hearing Loss , 2006, The Laryngoscope.

[21]  E. Diamandis Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[22]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[23]  J. Yates,et al.  Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. , 1995, Analytical chemistry.

[24]  G. Opiteck,et al.  Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.

[25]  P. Lewindon,et al.  Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. , 2004, Journal of hepatology.

[26]  T. Veenstra,et al.  Characterization of the Low Molecular Weight Human Serum Proteome*S , 2003, Molecular & Cellular Proteomics.

[27]  D Markiewicz,et al.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). , 1990, The New England journal of medicine.

[28]  N. Fujimoto,et al.  Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[29]  P. Leopold,et al.  Mass mapping of cancer cell lysates using two‐dimensional liquid separations, electrospray‐time of flight‐mass spectrometry, and automated data processing , 2005, Electrophoresis.

[30]  Werner Zolg,et al.  Quantification of C‐reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C‐labeled peptide standards , 2004, Proteomics.

[31]  V. Bramwell,et al.  Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[32]  Manfred Schmitt,et al.  Tumor Markers , 2003, Molecular & Cellular Proteomics.

[33]  Thomas Laurell,et al.  High‐speed biomarker identification utilizing porous silicon nanovial arrays and MALDI‐TOF mass spectrometry , 2006, Electrophoresis.

[34]  E. Diamandis,et al.  Purification and Characterization of Human Kallikrein 11, a Candidate Prostate and Ovarian Cancer Biomarker, from Seminal Plasma , 2006, Clinical Cancer Research.

[35]  Ewa Wójcik,et al.  Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis , 2006, Oncology.

[36]  S. Gygi,et al.  Measuring gene expression by quantitative proteome analysis. , 2000, Current opinion in biotechnology.

[37]  K. Arnold,et al.  Lipid analysis by matrix-assisted laser desorption and ionization mass spectrometry: A methodological approach. , 1999, Analytical biochemistry.

[38]  U. Stenman,et al.  Preoperative serum concentration of hCGβ as a prognostic factor in ovarian cancer , 2001, International journal of cancer.

[39]  A. Dunky,et al.  Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome , 2004, Arthritis research & therapy.

[40]  P. Sorger,et al.  Profiling receptor tyrosine kinase activation by using Ab microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[42]  D. Katsaros,et al.  Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Yocum,et al.  Effect of immunoaffinity depletion of human serum during proteomic investigations. , 2005, Journal of proteome research.

[44]  A. McGill,et al.  Concentrations of trypsin, elastase and carbohydrate antigen CA 19-9 in serum of cystic fibrosis patients. , 1986, Clinical chemistry.

[45]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[46]  Ronald C. Beavis,et al.  Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. , 1991, Analytical chemistry.

[47]  Yoshiya Oda,et al.  Mass spectrometry-based quantitative proteomics , 2007, Biotechnology & genetic engineering reviews.

[48]  C. Paweletz,et al.  Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  M. R. Wall,et al.  A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis , 2007, Journal of Molecular Neuroscience.

[50]  N. Rifai,et al.  Inflammatory markers in men with angiographically documented coronary heart disease. , 1999, Clinical chemistry.

[51]  M. Schrader,et al.  Peptidomics technologies for human body fluids. , 2001, Trends in biotechnology.

[52]  J. Bidart,et al.  CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[53]  E. Solomon,et al.  Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. , 2003, Gynecologic oncology.

[54]  David J. Anderson,et al.  Gradient chromatofocusing. versatile pH gradient separation of proteins in ion-exchange HPLC: characterization studies. , 2002, Analytical chemistry.

[55]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[56]  G. Rice,et al.  An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum , 2003, Proteomics.

[57]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[58]  M. Piccart,et al.  Use of tumour markers in monitoring the course of ovarian cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  J. Whitelegge Tandem mass spectrometry of integral membrane proteins for top-down proteomics , 2005 .

[60]  E. Diamandis,et al.  Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications , 2002 .

[61]  S. Yamaguchi,et al.  Ovarian malignant mixed mesodermal tumor producing the free form of the β-subunit of human chorionic gonadotropin , 2001, International Journal of Clinical Oncology.

[62]  B. Månsson,et al.  Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. , 1995, The Journal of clinical investigation.

[63]  M. Schindl,et al.  Interleukin‐8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel‐containing chemotherapy , 2001, Cancer.

[64]  G. Kramer,et al.  Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles , 2006, British Journal of Cancer.

[65]  R. Aebersold,et al.  Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry , 2001, Nature Biotechnology.

[66]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[67]  N Rifai,et al.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.

[68]  A. Zissimopoulos,et al.  [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer]. , 2006, Hellenic journal of nuclear medicine.

[69]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[70]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[71]  Carole Mathelin,et al.  Serum biomarkers for detection of breast cancers: a prospective study , 2006, Breast Cancer Research and Treatment.

[72]  G. Torre,et al.  Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[73]  G. Rice,et al.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer , 2004, British Journal of Cancer.

[74]  T. D. de Gruijl,et al.  Dendritic cells: a novel therapeutic modality. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[76]  G. Tedeschi,et al.  Characterization of nitroproteome in neuron‐like PC12 cells differentiated with nerve growth factor: Identification of two nitration sites in α‐tubulin , 2005, Proteomics.

[77]  T. Haystead,et al.  Molecular Biologist's Guide to Proteomics , 2002, Microbiology and Molecular Biology Reviews.

[78]  V. Berejnov,et al.  Measurements of protein-protein interactions by size exclusion chromatography. , 2003, Biophysical journal.

[79]  M. Dewhirst,et al.  Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma , 2004, Cancer.

[80]  A. Scorilas,et al.  Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry, and microarrays. , 2000, Clinical chemistry.

[81]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[82]  C C Schulman,et al.  PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. , 1999, Urology.

[83]  K. Pavelka,et al.  Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein , 2005, Annals of the rheumatic diseases.

[84]  J. Richie,et al.  Chromatofocusing fractionation and two‐dimensional difference gel electrophoresis for low abundance serum proteins , 2005, Proteomics.

[85]  G. Yousef,et al.  Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. , 2003, Cancer research.

[86]  M. Dunn,et al.  Genomics, proteomics and bioinformatics of human heart failure , 2004, Journal of Muscle Research & Cell Motility.

[87]  L. Pomorski,et al.  Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically. , 2004, Endocrine regulations.

[88]  L. Wodicka,et al.  Genome-wide expression monitoring in Saccharomyces cerevisiae , 1997, Nature Biotechnology.

[89]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[90]  D. Lashkari,et al.  High-throughput genomic and proteomic analysis using microarray technology. , 2001, Clinical chemistry.

[91]  M. Fujimoto,et al.  Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. , 2000, Journal of the American Academy of Dermatology.

[92]  Debashis Ghosh,et al.  Humoral Immune Response to α-Methylacyl-CoA Racemase and Prostate Cancer , 2004 .

[93]  Kan Zhu,et al.  Two-dimensional liquid separations-mass mapping of proteins from human cancer cell lysates. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[94]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[95]  F. Miller,et al.  Profiling the progression of cancer: Separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis , 2003, Proteomics.

[96]  S. Somiari,et al.  Functional Relationship and Gene Ontology Classification of Breast Cancer Biomarkers , 2003 .

[97]  A. Howell,et al.  Prospective assessment of the role of five tumour markers in breast cancer , 2005, Cancer Immunology, Immunotherapy.

[98]  A. Alaiya,et al.  Clinical cancer proteomics: promises and pitfalls. , 2005, Journal of proteome research.

[99]  Y. Ichinose,et al.  Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. , 2005, European journal of cancer.

[100]  A W Partin,et al.  The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. , 1998, Seminars in urologic oncology.

[101]  S Kennedy,et al.  Proteomic profiling from human samples: the body fluid alternative. , 2001, Toxicology letters.

[102]  J R Yates,et al.  Emerging tandem-mass-spectrometry techniques for the rapid identification of proteins. , 1997, Trends in biotechnology.

[103]  J. R. Reeves,et al.  A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. , 2006, The Journal of urology.

[104]  Laura Beretta,et al.  Proteomics for hepatocellular carcinoma marker discovery. , 2004, Gastroenterology.

[105]  M. Hogan,et al.  Simultaneous multianalyte ELISA performed on a microarray platform. , 2001, Clinical chemistry.

[106]  Stephen Russell,et al.  Proteomics of breast carcinoma. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[107]  B. Lollo,et al.  Improved two‐dimensional gel electrophoresis representation of serum proteins by using ProtoClearTM , 1999, Electrophoresis.

[108]  G. Banfi,et al.  Stability of tumor markers CA 19.9, CA 125, and CA 15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator. , 1997, Clinical chemistry.

[109]  J. Yates,et al.  DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. , 2002, Journal of proteome research.

[110]  Simon C. F. Sheng,et al.  Multidimensional Liquid Chromatography Separation of Intact Proteins by Chromatographic Focusing and Reversed Phase of the Human Serum Proteome , 2006, Molecular & Cellular Proteomics.

[111]  M. Duffy,et al.  Increased concentrations of the antigen CA-19-9 in serum of cystic fibrosis patients. , 1985, Clinical chemistry.

[112]  R. C. Mobley,et al.  Molecular Beams of Macroions , 1968 .

[113]  F. Miller,et al.  A two‐dimensional liquid‐phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification , 2004, Proteomics.

[114]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[115]  Ruedi Aebersold,et al.  Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. , 2002, Journal of proteome research.

[116]  G. Hortobagyi,et al.  Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. , 1983, JAMA.

[117]  K. Tanikawa,et al.  Vascular endothelial growth factor in patients with rheumatoid arthritis. , 1998, Scandinavian journal of rheumatology.

[118]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[119]  D. Chan,et al.  The Application of Clinical Proteomics to Cancer and other Diseases , 2003, Clinical chemistry and laboratory medicine.

[120]  G. Nicol,et al.  Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. , 2005, Journal of proteome research.

[121]  Jennifer N. Sutton,et al.  Reversed-phase HPLC separation of human serum employing a novel saw-tooth gradient: toward multidimensional proteome analysis. , 2004, Journal of proteome research.

[122]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .

[123]  M. Mann,et al.  Proteomics to study genes and genomes , 2000, Nature.

[124]  E. Petricoin,et al.  Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.

[125]  L. Yam Clinical significance of the human acid phosphatases: a review. , 1974, The American journal of medicine.

[126]  K. Syrigos,et al.  Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma , 1998, Gut.

[127]  A. Bosserhoff,et al.  MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. , 1999, Rheumatology.

[128]  M. Corey,et al.  Age-related alterations in immunoreactive pancreatic lipase and cationic trypsinogen in young children with cystic fibrosis. , 1985, The Journal of pediatrics.

[129]  Mark S Friedrichs,et al.  Changes in the protein expression of yeast as a function of carbon source. , 2003, Journal of proteome research.

[130]  B. Schmidt-Rohlfing,et al.  Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis , 2006, Rheumatology International.

[131]  Nuzhat Ahmed,et al.  Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer , 2005, Proteomics.

[132]  E. Sproul,et al.  Significance of Increased Phosphatase Activity of Bone at the Site of Osteoplastic Metastases Secondary to Carcinoma of the Prostate Gland , 1936 .

[133]  T. M. Chu,et al.  Fundamental biochemical and immunological aspects of prostatic acid phosphatase , 1980, The Prostate.

[134]  Hammond Eh,et al.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. , 1995 .

[135]  E Gianazza,et al.  Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. , 1982, Journal of biochemical and biophysical methods.

[136]  J. Ellner,et al.  Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[137]  J. Yates,et al.  Direct analysis of protein complexes using mass spectrometry , 1999, Nature Biotechnology.

[138]  Martin Sommer,et al.  Array-based multiplexed screening and quantitation of human cytokines and chemokines. , 2002, Journal of proteome research.

[139]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[140]  N. Ishikawa,et al.  Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma. , 2001, Thyroid : official journal of the American Thyroid Association.

[141]  Y. Fujiuchi,et al.  Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. , 2005, European urology.

[142]  B. Illek,et al.  Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[143]  A. Poole,et al.  The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. , 2004, Journal of immunological methods.

[144]  D. Hochstrasser,et al.  The dynamic range of protein expression: A challenge for proteomic research , 2000, Electrophoresis.

[145]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[146]  G. Opiteck,et al.  Biomarker discovery in biological fluids. , 2005, Methods.

[147]  D. Landsittel,et al.  Multiplexed Analysis of Serum Cytokines as Biomarkers in Squamous Cell Carcinoma of the Head and Neck Patients , 2005, The Laryngoscope.

[148]  J. Fenn,et al.  Electrospray ion source: another variation on the free-jet theme , 1984 .

[149]  J. Cummings Clinical evaluation as a biomarker for Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[150]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[151]  M. Rubin,et al.  Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer , 2005, British Journal of Cancer.

[152]  A. Nir,et al.  Natriuretic peptides and heart disease in infants and children. , 2005, The Journal of pediatrics.

[153]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[154]  H. Klocker,et al.  Derivatized cellulose combined with MALDI-TOF MS: a new tool for serum protein profiling. , 2005, Journal of proteome research.

[155]  Debashis Ghosh,et al.  Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. , 2004, Journal of the National Cancer Institute.

[156]  A. P. Arruda,et al.  Hyperthyroidism increases the uncoupled ATPase activity and heat production by the sarcoplasmic reticulum Ca2+-ATPase. , 2003, The Biochemical journal.

[157]  Stephen Russell,et al.  High‐throughput proteomic analysis of human infiltrating ductal carcinoma of the breast , 2003, Proteomics.

[158]  S M Hanash,et al.  Biomedical applications of two‐dimensional electrophoresis using immobilized pH gradients: Current status , 2000, Electrophoresis.

[159]  David E. Misek,et al.  Isoelectric focusing nonporous RP HPLC: a two-dimensional liquid-phase separation method for mapping of cellular proteins with identification using MALDI-TOF mass spectrometry. , 2000, Analytical chemistry.

[160]  J. Yates,et al.  An automated multidimensional protein identification technology for shotgun proteomics. , 2001, Analytical chemistry.

[161]  G. Jackowski,et al.  Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. , 2004, Journal of proteome research.

[162]  N G Anderson,et al.  High resolution two-dimensional electrophoresis of human plasma proteins. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[163]  J. Carmody,et al.  Mass profiling‐directed isolation and identification of a stage‐specific serologic protein biomarker of advanced prostate cancer , 2005, Proteomics.

[164]  S. Srivastava,et al.  Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. , 2005, Endocrine-related cancer.

[165]  S. Era,et al.  Age-related change in redox state of human serum albumin. , 1994, Biochimica et biophysica acta.

[166]  V. Gold,et al.  Compendium of chemical terminology : IUPAC recommendations , 1987 .

[167]  Peng-Yuan Yang,et al.  Heat‐shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysis , 2005, Proteomics.

[168]  Fang Wang,et al.  The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two‐dimensional electrophoresis gels and identification of 325 distinct proteins , 2003, Proteomics.

[169]  Yan-ming Lu,et al.  [Levels of serum interleukin-15 and the expression of T-helper lymphocyte subsets in peripheral blood of children with juvenile rheumatoid arthritis]. , 2006, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics.

[170]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[171]  J. An,et al.  Differential display of proteins involved in the neural differentiation of mouse embryonic carcinoma P19 cells by comparative proteomic analysis , 2005, Proteomics.

[172]  R. Sherwood,et al.  Liver Disease and Laboratory Medicine , 2000 .

[173]  G. Giannelli,et al.  MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. , 2004, Clinical and Experimental Rheumatology.

[174]  S. Orencole,et al.  Array-based ELISAs for high-throughput analysis of human cytokines. , 2001, BioTechniques.

[175]  Li Mao,et al.  Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry , 2004, Clinical & Experimental Metastasis.

[176]  Stephen Barnes,et al.  Prospective highlights of functional skin proteomics. , 2005, Mass spectrometry reviews.

[177]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[178]  J. Richie,et al.  Prostate carcinoma tissue proteomics for biomarker discovery , 2003, Cancer.

[179]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[180]  B. Mattiasson,et al.  Size exclusion behavior of hydroxypropylcellulose beads with temperature-dependent porosity. , 2001, Journal of chromatography. A.

[181]  H. Kanetake,et al.  Serum insulin‐like growth factor binding protein‐3/prostate‐specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer , 2003, The Prostate.

[182]  A. Görg,et al.  Current two‐dimensional electrophoresis technology for proteomics , 2004, Proteomics.

[183]  Ding‐Shinn Chen,et al.  Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV‐related hepatocellular carcinoma using a proteomics approach , 2006, Proteomics.

[184]  Koichi Tanaka,et al.  Protein and polymer analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry , 1988 .

[185]  A. Scorilas,et al.  Human kallikrein 10: a novel tumor marker for ovarian carcinoma? , 2001, Clinica chimica acta; international journal of clinical chemistry.

[186]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[187]  T. Acker,et al.  Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor‐2 dominant‐negative receptor mutants , 2001, International journal of cancer.

[188]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[189]  Roger E Bumgarner,et al.  Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. , 2001, Science.

[190]  M. Karas,et al.  Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. , 1988, Analytical chemistry.

[191]  À. Bayés,et al.  Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation , 2004, Biological chemistry.

[192]  K. Clauser,et al.  Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[193]  S. Gammeltoft,et al.  Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study , 2005, BMC Cancer.

[194]  S. Gygi,et al.  Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[195]  M J Dunn,et al.  Zooming‐in on the proteome: Very narrow‐range immobilised pH gradients reveal more protein species and isoforms , 2001, Electrophoresis.

[196]  A. Scorilas,et al.  Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study , 2006, Tumor Biology.

[197]  M. Kondo,et al.  Serum B12 Tryptase Level as a Marker of Allergic Airway Inflammation in Asthma , 2002, The Journal of asthma : official journal of the Association for the Care of Asthma.

[198]  T. Born,et al.  Use of surface‐enhanced laser desorption/ionization ‐time of flight to explore bacterial proteomes , 2004, Proteomics.

[199]  D. Hochstrasser,et al.  Industrial‐scale proteomics: From liters of plasma to chemically synthesized proteins , 2004, Proteomics.

[200]  M. Williams,et al.  The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[201]  J. Hollander,et al.  Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.

[202]  W. Busse,et al.  Evaluation of serum eosinophil cationic protein as a predictive marker for asthma exacerbation in patients with persistent disease , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[203]  R. Murphy Molecular mechanisms underlying gouty inflammation , 2006, Nature Clinical Practice Rheumatology.

[204]  Colin Eaborn,et al.  Compendium of chemical Terminology: IUPAC Recommendations , 1988 .

[205]  E. Maltezos,et al.  Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. , 2006, The American journal of cardiology.

[206]  M. Fukunaga,et al.  Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: a comparative study. , 1976, Endocrinologia japonica.

[207]  P. Johnson,et al.  The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. , 2001, Clinics in liver disease.

[208]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[209]  S. Fleming Liver Disease and Laboratory Medicine. I. McFarlane, A. Bomford, and R. Sherwood. London: ACB Venture Publications, 2000. , 2001 .

[210]  K. Ekdahl,et al.  Analysis of immunoglobulin isotype levels in acute pneumococcal bacteremia and in convalescence , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[211]  P. Riederer,et al.  “Subcellular Proteomics” of Neuromelanin Granules Isolated from the Human Brain* , 2005, Molecular & Cellular Proteomics.

[212]  Ilan Beer,et al.  Evaluation of prefractionation methods as a preparatory step for multidimensional based chromatography of serum proteins , 2005, Proteomics.

[213]  J. Risteli,et al.  Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer. , 2004, Anticancer research.

[214]  J. X. Pang,et al.  Biomarker discovery in urine by proteomics. , 2002, Journal of proteome research.

[215]  Ronald J. Moore,et al.  Toward a Human Blood Serum Proteome , 2002, Molecular & Cellular Proteomics.

[216]  C. Hermans,et al.  Serum clara cell protein: a sensitive biomarker of increased lung epithelium permeability caused by ambient ozone. , 2000, Environmental health perspectives.

[217]  J. Wootton Clinical practice guidelines. , 1999, Journal of women's health & gender-based medicine.

[218]  H. Shimano,et al.  Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. , 2001, Life sciences.

[219]  L. Petrović-Rackov [Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid]. , 2006, Vojnosanitetski pregled.

[220]  B. Zetter,et al.  Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.

[221]  R. Sylvester,et al.  Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer , 1990, Cancer.

[222]  W. N. Burnette,et al.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. , 1981, Analytical biochemistry.

[223]  B. Yin,et al.  Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK‐8): identification as a mucin‐type molecule , 1997, International journal of cancer.

[224]  Yazawa,et al.  Serum concentrations of vascular endothelial growth factor in collagen diseases , 1998, The British journal of dermatology.

[225]  Charles C. Liu,et al.  Capillary electrophoresis‐electrospray‐mass spectrometry of nucleosides and nucleotides: Application to phosphorylation studies of anti‐human immunodeficiency virus nucleosides in a human hepatoma cell line , 2005, Electrophoresis.

[226]  D. Hochstrasser,et al.  Mass Spectrometry-Based Proteomics: Current Status and Potential Use in Clinical Chemistry , 2003, Clinical chemistry and laboratory medicine.

[227]  Nilanjan Chatterjee,et al.  Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[228]  D. Roberts,et al.  A serum test for cystic fibrosis using monoclonal antibody 19-9. , 1986, Archives of biochemistry and biophysics.

[229]  K. Bailey,et al.  Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study , 2004, Circulation.

[230]  K. Hori,et al.  Testicular seminoma with human chorionic gonadotropin production , 1997, Pathology international.

[231]  Rick Wiese,et al.  Simultaneous analysis of eight human Th1/Th2 cytokines using microarrays. , 2002, JIM - Journal of Immunological Methods.

[232]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[233]  S. Ménard,et al.  Protein profile changes in the human breast cancer cell line MCF‐7 in response to SEL1L gene induction , 2005, Proteomics.

[234]  Marie-Christine W. Gast,et al.  Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. , 2006, Trends in pharmacological sciences.

[235]  C. Yıldırım,et al.  Serum Levels of NT-ProBNP as an Early Cardiac Marker of Carbon Monoxide Poisoning , 2006, Inhalation Toxicology.

[236]  R. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? , 2004, Journal of the American College of Cardiology.

[237]  N. Arakawa,et al.  Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population , 2002, Heart.

[238]  O. J. Semmes,et al.  Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers* , 2006, Molecular & Cellular Proteomics.

[239]  P. Vihko Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. , 1979, Investigative urology.

[240]  K. Chong-Kook,et al.  Identification of hemoglobin‐α and ‐β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer , 2005, Cancer science.

[241]  J. Donnelly,et al.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. , 2004, The Lancet. Infectious diseases.

[242]  S. Nordling,et al.  A comparison of serum and tissue hCG beta as prognostic markers in colorectal cancer. , 2000, Anticancer research.

[243]  Z. Bartoszewicz,et al.  Biomarker-based risk assessment model in acute pulmonary embolism. , 2005, European heart journal.

[244]  Ziad J. Sahab,et al.  Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis. , 2005, Journal of proteome research.

[245]  François Tron,et al.  Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[246]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[247]  Alain Van Dorsselaer,et al.  Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. , 2006, Journal of proteome research.

[248]  Min-Seok Kwon,et al.  Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. , 2006, Current opinion in chemical biology.

[249]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[250]  Richard D. Smith,et al.  Proteome analysis by mass spectrometry. , 2003, Annual review of biophysics and biomolecular structure.

[251]  A. Komiyama,et al.  Increased serum concentration of urinary trypsin inhibitor with asthma exacerbation , 2003, European Respiratory Journal.

[252]  J. Kropf,et al.  Evaluation of Cellular Fibronectin Plasma Levels as a Useful Staging Tool in Different Stages of Transitional Cell Carcinoma of the Bladder and Renal Cell Carcinoma , 2007, Biomarker insights.

[253]  Kathryn S Lilley,et al.  Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. , 2002, Current opinion in chemical biology.

[254]  S. Varnum,et al.  Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. , 2002, Journal of proteome research.

[255]  T. Poon,et al.  Structures of disease-specific serum alpha-fetoprotein isoforms , 2000, British Journal of Cancer.

[256]  J. Thompson,et al.  Trends in serum citrulline and acute rejection among recipients of small bowel transplants. , 2004, Transplantation proceedings.